Cerci K, Patir P. Ruxolitinib as a therapy choice for refractory pruritus in a patient with essential thrombocythemia with CALR mutation. Glob J Medical Clin Case Rep [Internet]. 2023 Jan. 25 [cited 2025 Jan. 1];10(1):001-2. Available from: https://www.organscigroup.com/gjmccr/article/view/GJMCCR-10-267